ASH Annual Meeting

Daratumumab Leads to PFS Improvement in Patients With Transplant-Ineligible Myeloma

December 11, 2019

A significant proportion of patients with transplant-ineligible newly diagnosed multiple myeloma alive and progression free after >3 years following treatment with daratumumab in addition to standard first-line therapy, according to updated safety and efficacy findings from the randomized ALCYONE study.

Impressive Results Continue With Updated Data on bb21217 in Multiple Myeloma

December 11, 2019

In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.

Transfusion Burden Reduction Seen With Luspatercept in Patients With Transfusion-Dependent Beta-Thalassemia

December 11, 2019

In the phase III BELIEVE trial, clinically meaningful and durable transfusion burden reduction were observed with luspatercept in the majority of adult patients with β-thalassemia who require regular red blood cell. Additionally, dose levels were not associated with by incidence of adverse events, and these AEs decreases overtime without affecting treatment modification or continuation.

Bispecific Antibody Demonstrates Antitumor Activity in Heavily Pretreated NHL

December 11, 2019

Treatment with REGN1979, a human anti-CD20 × anti-CD3 bispecific IgG4 antibody, showed high clinical activity and tolerability in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

BET Inhibitor Combination Induces Spleen and Symptom Responses in Myelofibrosis

December 11, 2019

CPI-0610, a selective and potent oral bromodomain and extra-terminal domain inhibitor, induced spleen and symptom responses as early as 12 weeks in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis, according to the preliminary findings from the phase II MANIFEST trial presented at the 2019 ASH Annual Meeting.

Across Subtypes of B-cell NHL, REGN1979 Produces Promising Responses

December 11, 2019

Heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma demonstrated antitumor activity when treated with varying dose levels of the human IgG4-based anti-CD20 × anti-CD3 bispecific monoclonalantibody, REGN1979.

GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRD

December 10, 2019

Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.

Navitoclax Shows Activity in Ruxolitinib-Resistant Patients With Myelofibrosis

December 10, 2019

Patients with primary or secondary myelofibrosis who developed resistance to ruxolitinib in the frontline setting, showed clinically meaningful spleen responses and improvements in symptoms with the addition of navitoclax to ruxolitinib, according to findings from a phase II study presented at the 2019 ASH Annual Meeting.

CC-486 Maintenance Extends OS in Older Patients With Acute Myeloid Leukemia

December 10, 2019

An extended media overall survival of 9.9 months was achieved with CC-486 maintenance treatment compared with placebo for older patients with acute myeloid leukemia in first remission, according to findings from the phase III QUAZAR AML-001 trial presented at the 2019 American Society of Hematology Annual Meeting.

Acalabrutinib Sustains Benefit In Patients With R/R CLL After 42 Months

December 10, 2019

Ongoing benefits of 42 months were observed with Bruton’s tyrosine kinase inhibitor acalabrutinib treatment in patients with relapsed/refractory chronic lymphocytic leukemia, according to long-term follow-up data from the phase I/II ACE-CL-001 study reported at the 2019 American Society of Hemetology Annual Meeting.